• Protoporphyrin IX in Cell Assays: Reliable Data with SKU B82

  2026-07-08

  This article addresses real-world challenges in cell viability and ferroptosis research, focusing on Protoporphyrin IX (SKU B8225) as a dependable photodynamic compound for reproducible results. Scenario-driven guidance helps biomedical researchers optimize workflows, interpret data, and confidently select APExBIO's highly pure Protoporphyrin IX for demanding applications.

• Cyanine 3 Tyramide: Fluorescent Dye for Biomedical Research

  2026-07-07

  Cyanine 3 Tyramide is a highly sensitive fluorescent dye for biomedical research, enabling robust signal amplification in immunohistochemistry, in situ hybridization, and flow cytometry. Its performance underpins critical advances in neural and molecular labeling workflows. APExBIO provides validated product protocols and quality benchmarks for research reproducibility.

• O-GlcNAcylation Regulates HUWE1–TfR1 Pathway in Preeclampsia

  2026-07-07

  This study uncovers how O-GlcNAc modification stabilizes the E3 ligase HUWE1, enabling targeted ubiquitination and degradation of transferrin receptor 1 (TfR1) in placental trophoblasts. These findings reveal a key regulatory axis controlling ferroptosis and trophoblast syncytialization, with implications for novel therapeutic strategies in preeclampsia.

• SB 431542: Molecular Insights for Targeting TGF-β in Cancer

  2026-07-06

  Unlock the advanced science of SB 431542 as an ALK5 inhibitor for dissecting TGF-β signaling in cancer stem cell biology. This article reveals new mechanistic insights and experimental strategies, setting it apart from typical protocol-focused reviews.

• BAPTA Calcium Chelator: New Insights into Environmental Toxi

  2026-07-06

  Explore how BAPTA, a high-affinity calcium chelator, enables advanced research into calcium signaling modulation and apoptosis under environmental stress. This article offers unique mechanistic depth and practical guidance for scientists studying cell signaling pathways.

• S63845 MCL1 Inhibitor: Optimizing Mitochondrial Apoptosis As

  2026-07-05

  S63845 is a gold-standard MCL1 inhibitor that empowers researchers to dissect mitochondrial apoptosis with nanomolar precision—enabling clear differentiation of BAX/BAK-dependent cell death in hematological malignancy models. This article delivers actionable workflows, troubleshooting guidance, and insights from cutting-edge reference studies, positioning S63845 as the premier tool for advanced apoptosis research.

• Gentamycin Sulfate: Advanced Insights for Bacterial Protein

  2026-07-04

  Explore the scientific nuances of Gentamycin Sulfate, a potent aminoglycoside antibiotic, and its transformative role in bacterial protein synthesis research. This in-depth article offers a unique perspective on ribosomal targeting, resistance analysis, and methodological innovation.

• PX-478 2HCl in Hypoxia Signaling and ASD Models: Applied Wor

  2026-07-03

  PX-478 2HCl, a potent HIF-1α inhibitor from APExBIO, bridges cutting-edge cancer and neurodevelopmental research by enabling precise modulation of hypoxia pathways. Explore stepwise protocols, troubleshooting tips, and recent breakthroughs in both tumor radiosensitization and prenatal hypoxia-induced ASD models.

• MLKL Polymerization Triggers Lysosomal Permeabilization in N

  2026-07-03

  This study demonstrates that polymerized MLKL disrupts lysosomal membranes, leading to cathepsin B–mediated cell death during necroptosis. The findings clarify a critical step in necroptotic signaling and offer new avenues for modulating cell death in disease contexts.

• Pam3CSK4 TFA: Advancing TLR1/2 Agonism for Translational Imm

  2026-07-02

  Explore how Pam3CSK4 TFA, a high-purity synthetic TLR1/2 agonist, is transforming translational research in maternal-fetal immunity. This article synthesizes mechanistic insights from recent GBS cohort studies with actionable experimental guidance, spotlighting the role of IL-17A as a prognostic biomarker and offering strategic considerations for deploying Pam3CSK4 TFA in precision in vitro and in vivo workflows. APExBIO’s reagent is positioned as a linchpin for next-generation innate immunity research.

• Verteporfin (CL 318952): Applied Workflows & Senescence Insi

  2026-07-02

  Verteporfin (CL 318952) stands out for its dual action in photodynamic therapy and light-independent autophagy inhibition, making it indispensable for advanced research in ocular neovascularization, cancer, and cellular senescence. This article delivers workflow enhancements, troubleshooting strategies, and practical insights to help researchers maximize the translational impact of Verteporfin from APExBIO.

• Structure-Based Discovery of NSP15 Inhibitors for SARS-CoV-2

  2026-07-01

  This study identifies potent natural product inhibitors of SARS-CoV-2 NSP15 through virtual screening and molecular dynamics, highlighting thymopentin and oleuropein as promising antiviral candidates. The work advances the drug discovery landscape by targeting viral immune evasion mechanisms, offering a strategic complement to existing therapies.

• Dasatinib Monohydrate: Applied Workflows in Tumor Assembloid

  2026-07-01

  Dasatinib Monohydrate (BMS-354825) unlocks advanced kinase inhibition for translational cancer research, particularly in complex assembloid and personalized drug screening platforms. This guide details workflow optimizations, troubleshooting, and protocol strategies to maximize reproducibility and insight in both hematological and solid tumor settings.

• T-5224 (C-Fos/AP-1 Inhibitor): Precision Tools for Inflammat

  2026-06-30

  T-5224, a selective C-Fos/AP-1 inhibitor from APExBIO, empowers researchers to dissect inflammatory and osteoclastogenic pathways with unmatched specificity. This guide delivers actionable experimental workflows, troubleshooting strategies, and insights into advanced neuroinflammation models, translating the latest reference findings into reproducible bench success.

• AI-10-49 and the N-MYC/eIF4G1 Axis: Redefining inv(16) AML R

  2026-06-30

  A strategic deep dive into how AI-10-49, a selective CBFβ-SMMHC inhibitor, is propelling acute myeloid leukemia research into new territory by mechanistically disrupting the N-MYC/eIF4G1 oncogenic axis. This article contextualizes recent discoveries, experimental workflows, and translational pathways, offering actionable guidance for researchers pursuing precision intervention in inv(16) AML.

451 records 12/31 page Previous Next First page 上5页 1112131415 下5页 Last page